The inability of 2D cell culture systems to fully translate preclinical drug behaviour into meaningful clinical efficacy or safety is a key contributing factor to high attrition rates in drug discovery programs. As in vitro biological testing is one of the most crucial early steps in the development of novel therapeutics, advancement within this area plays a key role in the evolution of drug discovery.
With the promise of bridging the gap between effective preclinical drug screening and predicting therapeutic success in patient clinical trials, the development of 3D models has taken flight over the last decade. Now, the use of 3D organoids at the early stages of drug discovery processes can promote selection of more efficacious and safer drug candidates.
This webcast will present how organoid platforms can be used to identify novel antivirals, as well as to interrogate vaccine responses in complex human tissue models.
Learn:
• How 3D organoids can mimic relevant human physiology more closely than most existing systems
• How organoid technology is being incorporated into infectious disease drug screening cascades and discovery workflows
• Why more sophisticated human 3D models will greatly minimise use of animals in drug discovery
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Charles River Laboratories, who retails sole responsibility for content. About this content.
Speakers
Ludovico Buti, Senior Research Leader, Charles River in Leiden, The Netherlands
Ludovico Buti, PhD, is a senior research leader at the biology department of Early Discovery of Charles River in Leiden, The Netherlands. He has established 3D organoid models to study host-pathogen interactions and used this ex vivo system to develop and validate new antimicrobial molecules against infection with bacterial and viral pathogens.
Dan Rocca, Research Leader, Charles River in Portishead, UK
Dr. Dan Rocca is a research leader in Innovation at Charles River Labs. His previous expertise included developing Organ-on-Chip models, Synthetic Biology and Neuroscience. He is currently exploring novel immune organoids to better mimic human adaptive immune responses in vaccine and infectious disease drug discovery.
Moderator
Nikki Forrester, Freelance Science Writer and Editor
Nikki Forrester is a science journalist who covers biology, natural history, climate, and the culture of academic research. She earned a Ph.D. in ecology and evolutionary biology in 2019.
